Clinical olfactory tests are used to address hyposmia/anosmia levels in patients with different types of olfactory impairments. Typically, a given test is employed clinically and then replaced by a new one after a certain period of use which can range from days to several months. There is a need to assess control quality of these tests and also for a procedure to quantify their degradation over time. In this paper we propose a protocol to employ low-cost artificial noses for the quantitative characterization of olfactory tests used in clinical studies. In particular, we discuss a preliminary study on the Connecticut Chemosensorial Clinical Research Center Test kit which shows that some odorants, as sensed by an artificial nose, seem to degrade while others are potentiated as the test ages. We also discuss the need to establish a map of correspondence between human and machine olfaction when artificial noses are used to characterize or compare human smell performance in research and clinical studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270573 | PMC |
http://dx.doi.org/10.3389/fneng.2012.00001 | DOI Listing |
Front Neurosci
January 2025
Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Capital Medical University, Beijing, China.
Purpose: To investigate the changes in cerebral hemispheric functional connections in patients with acute acquired concomitant esotropia (AACE) and their relationship with clinical manifestations, utilizing voxel-mirrored homotopic connectivity (VMHC).
Methods: A prospective, observational study was conducted involving 32 AACE patients and 31 age-, sex-, and education-matched healthy controls (HC). The resting-state functional magnetic resonance imaging (rs-fMRI) signals, binocular vision function, and psychometric scale scores were collected rs-fMRI data and structural image data were analyzed for VMHC, and a two-sample -test was used to analyze the differences in VMHC between groups.
Int Forum Allergy Rhinol
January 2025
Universidade Estadual de Londrina, Londrina, Brazil.
Background: Recent studies have extensively explored new non-invasive and side-effect-free therapeutic strategies for the treatment of allergic rhinitis (AR). Photobiomodulation therapy (PBMT) utilizes photons from the red to infrared spectrum to modulate biological processes, exhibiting anti-inflammatory and regenerative properties. The objective of our study was to evaluate the efficacy of PBMT in patients with AR.
View Article and Find Full Text PDFAm J Otolaryngol
January 2025
Department of Adult and Development Age Human Pathology "Gaetano Barresi", Unit of Otorhinolaryngology, University of Messina, Via Consolare Valeria 1, 98125 3, Italy. Electronic address:
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a type 2 pattern of inflammation. Mepolizumab was approved for the treatment of CRSwNP in 2021. However, there is a lack of real-life studies.
View Article and Find Full Text PDFCurr Allergy Asthma Rep
January 2025
Smell and Taste Clinic, Department of Otorhinolaryngology, Technical University of Dresden, Dresden, Germany.
Purpose Of Review: Parosmia is a qualitative olfactory disorder in which there is a mismatch between the memory of an odor and the actual experience triggered by an odor. There has been a surge in parosmia-related publications since the COVID-19 pandemic. This review summarizes the latest clinical findings, theories on pathophysiology and potential treatment options.
View Article and Find Full Text PDFInt J Eat Disord
January 2025
Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA.
Background: Individuals with avoidant/restrictive food intake disorder (ARFID) self-report heightened sensitivity to taste and smell, but neither phenomenon has been systematically explored in the laboratory. We hypothesized that, compared to healthy controls (HC, n = 34), children, adolescents, and adults with full/subthreshold ARFID (n = 100; ages 9 to 23 years) would self-report heightened response to taste/smell stimuli and exhibit stronger bitter taste perception and heightened smell perception in performance-based tasks, and these differences would be especially prominent in those with the ARFID-sensory sensitivity presentation.
Method: We measured self-reported sensitivity to taste/smell with the adolescent/adult sensory profile (AASP).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!